BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on ...

Analysts estimate that BridgeBio Pharma will report an earnings per share (EPS) of $-0.82. The announcement from BridgeBio ...

BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest ...

BioMarin no longer expects to hit its $4 billion revenue target by 2027, citing various market factors such as impending ...

Bridgebio Pharma says it will seek U.S. approval of BBP-418 for LGMD2i after Phase 3 trial data showed a range of benefits ...

Fintel reports that on October 27, 2025, HC Wainwright & Co. maintained coverage of BridgeBio Pharma (NasdaqGS:BBIO) with a ...

The search for a treatment for limb-girdle muscular dystrophy was started by the family of former Bank of America Corp. CEO ...

Stock indexes in the U.S. rose Monday with the rising 1.86%. Meanwhile, the added 1.23%, and the added 0.71%.

BridgeBio said an experimental therapy for a rare form of muscular dystrophy succeeded in a key trial, potentially setting up ...

The $12.5 billion acquisition of Avidity Biosciences Inc. by Novartis AG strengthens the company’s neuroscience pipeline and marks the second biggest deal that’s been announced this year. San ...

BridgeBio Pharma ( ($BBIO) ) has shared an announcement. On October 27, 2025, BridgeBio Pharma announced positive results from its Phase 3 FORTIFY ...

BridgeBio Pharma shares surge on positive BBP-418 trial results for limb-girdle muscular dystrophy. Read more here.